Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Silo Pharma, Inc.

< Previous 1 2 Next >
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.